Galvus “Approvable”: Additional Trial To Be Relatively Small, Short – Novartis
Executive Summary
FDA will likely require Novartis to conduct a clinical trial of the dipeptidyl peptidase-4 inhibitor Galvus in a relatively small number of patients that are predisposed to achieving high plasma levels with standard doses of the drug, Novartis Global Pharma Development Head James Shannon said
You may also be interested in...
Novartis Oncology Pipeline Has Three Potential Blockbusters In The Offing
Novartis is aiming to launch a trio of potential blockbuster oncology drugs in the next few years that the firm hopes will erase the memory of several recent high-profile setbacks in multiple therapeutic areas
Novartis Oncology Pipeline Has Three Potential Blockbusters In The Offing
Novartis is aiming to launch a trio of potential blockbuster oncology drugs in the next few years that the firm hopes will erase the memory of several recent high-profile setbacks in multiple therapeutic areas
Galvus Trial To Take Longer Than Predicted; Novartis Also Sees Tasigna Delay
Novartis is now facing a longer delay for its dipeptidyl peptidase-4 agent Galvus (vildagliptin) than previously predicted, since the safety study in patients with renal impairment requested by FDA will take at least six months, not "weeks" as originally suggested